Genzyme Reports Financial Results for the First Quarter of 2010
Links shared publicly online about this topic.
- 1,224total visits
Genzyme Reports Financial Results for the First Quarter of 2010
View full resource at businesswire.com
Tags: Gaucher Disease Medication, Cerezyme, Genzyme
Most Recently Shared on April 21, 2010 at 3:02 pm By:
Here's the Genzyme release on the $175M fine. Also includes new delays on Cerezyme supply. http://bit.ly/d0g0bV
Also Shared By:
Advanced Cell Technology first quarter net loss decreases to $3.3 million
news-medical.net — “Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today first quarter financial results for the period ended March 31, 2011. The Company reported a loss from operations of $(4.8) million compared to a loss from operations of $(15.0) million in the 2010 first quarter.” View full resource at news-medical.net
Most Recently Shared on May 9, 2011 at 3:12 pm By:
Advanced Cell Technology first quarter net loss decreases to $3.3 million: Advanced Cell Technology, Inc., a lea... http://bit.ly/jdHHp3
Caliper Life Sciences Reports First Quarter 2011 Results | IVD Technology
ivdtechnology.com — “Caliper Life Sciences Inc. reported its financial results for the first quarter of 2011. First quarter revenue increased to $35.8 million, or 25%, from $28.7 million in the same period of 2010. This increase was principally driven by year-over-year 26% organic growth of comparable product, service and license revenues. Cambridge Research & Instrumentation Inc. (CRi), which Caliper acquired in December 2010, contributed $2.6 million to first quarter 2011 revenues.” View full resource at ivdtechnology.com
Most Recently Shared on May 2, 2011 at 7:26 pm By:
IVD Technology Health Magazine
Caliper Life Sciences Reports First Quarter 2011 Results http://tinyurl.com/3hl7v47
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year - Drugs.com MedNews
drugs.com — “Recovery Continues with Growth Across All Businesses Feb 16, 2011 - Genzyme Corp. (NASDAQ GENZ) today reported fourth-quarter 2010 results that reflect increasi” View full resource at drugs.com
Most Recently Shared on February 16, 2011 at 2:13 pm By:
Drugs and Devices OW OW Health
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year: Recovery Continues with Growth... http://bit.ly/fk5Cyf #drug
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year | Business Wire
businesswire.com — “Genzyme Corp. (NASDAQ: GENZ) today reported fourth-quarter 2010 results that reflect increasing supplies of Cerezyme® (imiglucerase for injection)” View full resource at businesswire.com
Most Recently Shared on February 16, 2011 at 1:30 pm By:
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year http://bit.ly/eaHU23
Simulations Plus first quarter consolidated revenues increase 15.4% to record $2.811M
news-medical.net — “Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its first quarter of fiscal year 2011 ended November 30, 2010 (1QFY11).” View full resource at news-medical.net
Most Recently Shared on January 14, 2011 at 2:30 pm By:
Simulations Plus first quarter consolidated revenues increase 15.4% to record $2.811M: Simulations Plus, Inc., a... http://bit.ly/gTgdiE
Accelr8 reports $466,362 net sales revenue for first fiscal quarter ended October 31, 2010
news-medical.net — “Accelr8 Technology Corporation announced its financial results for the first fiscal quarter ended October 31, 2010. Net sales revenues totaled $466,362; net income from operations was $49,974 with total net income of $67,250. For the previous quarter, net sales were $15,549 with a loss from operations of $(423,373) and a total net loss of $(411,981). Shareholders' equity totaled $4,985,682 at the current quarter's end, up from $4,909,778 at the end of the previous fiscal quarter.” View full resource at news-medical.net
Most Recently Shared on December 17, 2010 at 7:51 am By:
Accelr8 reports $466,362 net sales revenue for first fiscal quarter ended October 31, 2010: Accelr8 Technology C... http://bit.ly/guPWju
Shengtai 2010 first quarter sales revenue increases 49.80% to $34,644,572
news-medical.net — “Shengtai Pharmaceutical, Inc., a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported financial results for the three months ended September 30, 2010.” View full resource at news-medical.net
Most Recently Shared on November 17, 2010 at 6:00 am By:
Shengtai 2010 first quarter sales revenue increases 49.80% to $34,644,572: Shengtai Pharmaceutical, Inc., a manu... http://bit.ly/9T5Xxy
SOKO Fitness & Spa Group to Report Fiscal First Quarter 2011 Financial Results on Wednesday, October 13, 2010 - Health News - redOrbit
redorbit.com — “HARBIN, China, Oct. 12 /PRNewswire-Asia-FirstCall/ -- SOKO Fitness & Spa Group, Inc.” View full resource at redorbit.com
Most Recently Shared on October 12, 2010 at 2:55 pm By:
SOKO Fitness & Spa Group to Report Fiscal First Quarter 2011 Financial Results on Wednesday, October 13, 2010: HAR... http://bit.ly/bMRDP7
China-Biotics net sales for first-quarter fiscal 2011 increase 61.8% to $24.9 million
news-medical.net — “China-Biotics, Inc., a leading developer, manufacturer and distributor of probiotics products in China, today reported its financial results for the first quarter of its 2011 fiscal year, ended June 30, 2010.” View full resource at news-medical.net
Most Recently Shared on August 9, 2010 at 11:28 am By:
China-Biotics net sales for first-quarter fiscal 2011 increase 61.8% to $24.9 million: China-Biotics, Inc., a lead... http://bit.ly/cyvl5N
Jazz Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 10 - Health News - redOrbit
redorbit.com — “PALO ALTO, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that it will report its second quarter 2010 financial results on Tuesday, August 10, 2010.” View full resource at redorbit.com
Most Recently Shared on August 3, 2010 at 12:11 am By:
Jazz Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 10: PALO ALTO, Calif., Aug. 2 /PR... http://bit.ly/b83Ufp
Endo Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results - Health News - redOrbit
redorbit.com — “CHADDS FORD, Pa., July 30 /PRNewswire-FirstCall/ -- Total quarterly revenues increase 6 percent versus prior year; branded drug sales up 8 percentReported diluted EPS of .44, up 69% from prior year; adjusted diluted EPS of .81, reflecting growth of 11 percent from 2009Company reiterates previous financial guidance of revenues in a range of .63B to .68BCompany increases adjusted diluted EPS to a range of .25 to .30 and now expects Reported or GAAP diluted EPS to be in a range of .99 to .07Endo Ph” View full resource at redorbit.com
Most Recently Shared on July 30, 2010 at 5:40 pm By:
Urology & Nephrology OW Health
Endo Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results: CHADDS FORD, Pa., July 30 /PRNewswire-F... http://bit.ly/azp9Zp
Encision reports 8% decline in first-quarter fiscal 2011 net sales
news-medical.net — “Encision Inc., a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its first fiscal quarter ended June 30, 2010.” View full resource at news-medical.net
Most Recently Shared on July 27, 2010 at 11:17 am By:
Encision reports 8% decline in first-quarter fiscal 2011 net sales: Encision Inc., a medical device company owning... http://bit.ly/b5doxX
Genzyme Reports Financial Results for the Second Quarter of 2010
businesswire.com — “CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year. GAAP net income was $23,000, or $0.00 per dilu” View full resource at businesswire.com
Most Recently Shared on July 21, 2010 at 2:08 pm By:
Genzyme Reports Financial Results for the Second Quarter of 2010 http://bit.ly/9lVns7
Inovio Pharmaceuticals Reports First Quarter 2010 Financial Results - News Press Release | PharmiWeb.com
pharmiweb.com — “Inovio Pharmaceuticals Reports First Quarter 2010 Financial Results - News Press Release | PharmiWeb.com” View full resource at pharmiweb.com
Most Recently Shared on May 18, 2010 at 2:14 pm By:
Press Release: Inovio Pharmaceuticals Inc. Posted on:18 May 10 Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today... http://bit.ly/b3xQoZ
Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010
news-medical.net — “Tengion Inc. today reported its financial results for the quarter ended March 31, 2010 and provided a corporate and clinical development update.” View full resource at news-medical.net
Most Recently Shared on May 18, 2010 at 2:01 pm By:
News-Medical.Net Health News and Oncology
Oncology News: Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter ... http://bit.ly/aNX0ES
Advertisement
Genzyme Corporation
@GenzymeCorp
Genzyme Reports Financial Results for the Second Quarter of 2010 http://bit.ly/9lVns7
1 year ago...